Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug

Stock Track11-27 14:32

Sichuan Kelun-Biotech Biopharmaceutical (SKB BIO-B) saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration (NMPA) for its breast cancer drug.

The approved drug, sacituzumab tirumotecan (sac-TMT), is designed to treat advanced or metastatic triple-negative breast cancer (TNBC) in adult patients who have already undergone at least two prior systemic therapies, including one for advanced or metastatic disease. The drug targets TROP2 using an antibody-drug conjugate and is intended for TNBC cases that cannot be surgically removed.

The positive regulatory development has bolstered investor confidence in SKB BIO-B's prospects, as the company can now commercialize the breast cancer drug in China's sizable healthcare market. Analysts will be closely monitoring the drug's market performance and potential revenue contribution to the company's financials.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136371661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136371661","market":"hk","top_or_hot":-1,"title":"Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug","media":"Stock Track","content":"<p>Sichuan Kelun-Biotech Biopharmaceutical (SKB BIO-B) saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration (NMPA) for its breast cancer drug.</p>\n\n<p>The approved drug, sacituzumab tirumotecan (sac-TMT), is designed to treat advanced or metastatic triple-negative breast cancer (TNBC) in adult patients who have already undergone at least two prior systemic therapies, including one for advanced or metastatic disease. The drug targets TROP2 using an antibody-drug conjugate and is intended for TNBC cases that cannot be surgically removed.</p>\n\n<p>The positive regulatory development has bolstered investor confidence in SKB BIO-B's prospects, as the company can now commercialize the breast cancer drug in China's sizable healthcare market. Analysts will be closely monitoring the drug's market performance and potential revenue contribution to the company's financials.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SKB BIO-B Soars 7.36% on NMPA Approval for Breast Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-27 14:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical (SKB BIO-B) saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物-B","start_time":0,"source_url":"","article_id":"1136371661","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136371661","pubTimestamp":1732689154,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sichuan Kelun-Biotech Biopharmaceutical  saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration  for its breast cancer drug.The approved drug, sacituzumab tirumotecan , is designed to treat advanced or metastatic triple-negative breast cancer  in adult patients who have already undergone at least two prior systemic therapies, incl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物-B"},"translate_title":"股票赛道SKB BIO-B因NMPA批准乳腺癌药物而飙升7.36%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (SKB BIO-B) saw its shares surge 7.36% in the intraday session on Wednesday, outperforming the broader market. The rally was fueled by the company receiving marketing authorization from China's National Medical Products Administration (NMPA) for its breast cancer drug.\nThe approved drug, sacituzumab tirumotecan (sac-TMT), is designed to treat advanced or metastatic triple-negative breast cancer (TNBC) in adult patients who have already undergone at least two prior systemic therapies, including one for advanced or metastatic disease. The drug targets TROP2 using an antibody-drug conjugate and is intended for TNBC cases that cannot be surgically removed.\nThe positive regulatory development has bolstered investor confidence in SKB BIO-B's prospects, as the company can now commercialize the breast cancer drug in China's sizable healthcare market. Analysts will be closely monitoring the drug's market performance and potential revenue contribution to the company's financials.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136371661"}